Document is current
Any future updates will be listed below
-
Authors
Jacoby, Elad https://orcid.org/0000-0003-1411-8942
Ben Yakir-Blumkin, Moriya
Blumenfeld-Kan, Shiri
Brody, Yehuda
Meir, Amilia
Melamed-Book, Naomi
Napso, Tina
Pozner, Gat
Saadi, Esraa
Shabtay-Orbach, Ayelet
Yivgi-Ohana, Natalie
Sher, Noa https://orcid.org/0000-0001-8992-1751
Toren, Amos
-
Funding
Funding for this research was provided by:
Champ foundation Minovia Therapeutics
- License Information
-
More Information
Article History
Received: 18 February 2021
Accepted: 19 August 2021
First Online: 24 September 2021
Competing interests
: M.B.B., S.B.K., Y.B., T.N., G.P., A.S.O., E.S., N.Y.O. and N.S. are employed by the company Minovia Therapeutics Ltd. N.Y.O. is a shareholder and a director of Minovia Therapeutics Ltd. N.Y.O. in an inventor on a pending patent application entitled “MAMMALIAN CELLS ENRICHED WITH FUNCTIONAL MITOCHONDRIA” (US20190330595A1). N.Y.O. and N.S. are inventors on a pending patent application entitled “MITOCHONDRIAL AUGMENTATION THERAPY WITH STEM CELLS ENRICHED WITH FUNCTIONAL MITOCHONDRIA” (US 17/252,674). Additionally, based on the data described in this study, M.B.B., N.Y.O. and N.S. are inventors on a provisional application titled “MITOCHONDRIAL AUGMENTATION THERAPY” and N.Y.O. and N.S. are inventors on a provisional application titled “IDENTIFICATION OF MITOCHONDRIA-ENRICHED CELLS”. During the period of the study, Minovia Therapeutics Ltd. received institution grants from the Israeli Innovation authority, unrelated to the current study. E.J., A.M., N.M.B. and A.T. have no financial conflict of interest.
